Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of the Selective Oral CCR2 Antagonist CNTX-6970 in Healthy Subjects

Authors
Category Primary study
ConferencePostgraduate Medicine
Year 2019
This article has no abstract
Epistemonikos ID: 5b987cd5f6018ea5b6a2c5fca83a1398d7456e8e
First added on: Apr 30, 2026